Ken-Opurum J, Srinivas SSS, Vadagam P, Faith L, Park S, Charland S, Revel A, Preblick R Axtria, Berkeley Heights, NJ, USA; Sanofi, Bridgewater, NJ, US
Atrial Fibrillation (AFib) is associated with considerable morbidity and mortality and is characterized by arrhythmia, tachycardia, and/or bradycardia, and symptoms often include heart palpitations, shortness of breath, and weakness.
The objective of this study was to evaluate the economic benefits of anti-arrhythmic drugs (AADs) in comparison to ablation, both as individual treatments and as combination therapy with/ without considering the order of treatment. A Rhythm Control Economic model was used to compare different treatment scenarios assess the economic benefits of AADs (dronedarone, amiodarone, sotalol, flecainide, propafenone, dofetilide, and AADs as a group) vs ablation. The results of the study bring forward interesting insights in comparison of direct and combination therapies.
Complete the brief form to download the report.
Contact us at insights@axtria.com with any questions.
